Why Is Worldwide Healthcare Trust Up Today?
Worldwide Healthcare Trust plc shares rose 0.13% today to around 380.00p, extending a period of renewed strength for the specialist global healthcare Investment trust following a strong return to form in its most recent financial year.
The gain reflects continued investor confidence in the trust's ability to navigate a challenging healthcare sector backdrop, having delivered meaningful outperformance against its benchmark despite ongoing US drug pricing and Tariff uncertainty.
Key Highlights
Worldwide Healthcare Trust's FY26 results, for the year ended 31 March 2026, showed NAV and share price total returns of 10.0% and 13.1% respectively, well ahead of the benchmark's 1.8% return. The trust's proprietary Biotech M&A Basket returned 55.9% in sterling terms, contributing 5.6 percentage points to the total return.
Since launch in April 1995, WWH has generated average annual NAV total returns of 13.3%, compared with 11.0% for the benchmark. The Company undertook a substantial buyback programme, spending £396.3 million to repurchase 24.5% of share capital, while the discount to NAV narrowed to 10.0%.
About Worldwide Healthcare Trust
Worldwide Healthcare Trust is a specialist investment trust that invests in the global healthcare sector, aiming to achieve a high level of capital growth by investing across pharmaceutical, biotechnology and related securities, using gearing and derivative transactions to enhance capital returns and mitigate risk.
The trust is co-managed by Sven Borho and Trevor Polischuk at OrbiMed, a major global specialist healthcare investor, with performance measured against the MSCI World Health Care index on a sterling-adjusted basis.
Key Reasons Behind Today's Gain
Today's gain builds on the trust's marked recovery through FY26, which management attributed to its continued focus on innovation and growth, particularly through biotechnology exposure via the proprietary Biotech M&A Basket, which significantly outperformed the broader market.
The managers believe the sector backdrop has improved following greater US policy clarity on drug pricing, while attractive biotech valuations, high levels of innovation and large pharma's Patent cliff should continue to support Merger and Acquisition activity, a dynamic that has already driven strong recent performance.
A Difficult FY25 Gives Way to Renewed Outperformance
Worldwide Healthcare Trust's FY26 results marked a notable turnaround following a difficult prior year, with the trust delivering NAV and share price total returns well ahead of its benchmark despite healthcare stocks remaining under pressure for much of the year due to ongoing drug pricing and tariff uncertainty in the US.
The trust's June 2026 monthly commentary further underscored this improving momentum, reporting a NAV per share total return of +9.6% and a share price total return of +10.2% for the month alone, as a broader market rotation out of technology and into lagging sectors such as healthcare took hold.
Biotech M&A Basket Drives Outsized Contribution
The trust's proprietary Biotech M&A Basket has been a standout contributor to recent performance, returning 55.9% in sterling terms and adding 5.6 percentage points to the FY26 total return, reflecting the managers' successful positioning around anticipated acquisition activity in the biotechnology sector.
This performance aligns with co-managers Sven Borho and Trevor Polischuk's broader thesis that large pharmaceutical companies facing patent cliffs, combined with attractive biotech valuations and continued high levels of innovation, should sustain robust M&A activity as a persistent tailwind for the sector.
Risks
Healthcare stocks remain subject to significant policy risk, particularly around US drug pricing, and any renewed deterioration in policy clarity could weigh on sector sentiment and reverse some of the trust's recent outperformance.
Performance has been uneven across healthcare subsectors, with the trust's own monthly commentary noting instances where 'positioning of the Trust was the primary driver of underperformance,' illustrating that stock selection risk remains a meaningful Factor for a concentrated, specialist portfolio.
The trust employs gearing to enhance capital returns, which can amplify losses as well as gains, and its reliance on continued biotech M&A activity as a key performance driver means any slowdown in dealmaking could affect future returns.
Valuation
Worldwide Healthcare Trust's valuation reflects a specialist healthcare fund that has delivered a strong recovery in performance, trading at a discount to NAV of around 7-10% following substantial share buyback activity that has already narrowed this discount meaningfully.
With average annual NAV total returns of 13.3% since launch, well ahead of the benchmark's 11.0%, and continued conviction in biotech M&A as a performance driver, the trust's long-term track record supports confidence in its differentiated approach to global healthcare investing.
What Investors Should Watch Next
Investors should monitor continued performance of the trust's Biotech M&A Basket, alongside broader developments in US drug pricing policy that could affect sentiment across the healthcare sector.
The trust's ongoing share buyback programme and its impact on the discount to NAV, alongside relative performance across different healthcare subsectors, will also be important factors for the stock.
Conclusion
Worldwide Healthcare Trust's 0.13% rise today extends a period of renewed strength following a strong FY26 recovery, with NAV and share price total returns well ahead of benchmark, powered significantly by the trust's proprietary Biotech M&A Basket.
With continued conviction in a supportive M&A backdrop driven by large pharma's patent cliff and attractive biotech valuations, alongside substantial share buyback activity narrowing the discount to NAV, Worldwide Healthcare Trust's positioning for continued sector-driven outperformance appears well supported.






Please wait processing your request...